European Commission grants orphan drug status to Eisai's amatuximab for the treatment of malignant mesothelioma

The investigational monoclonal antibody amatuximab (development code: MORAb-009), has been granted orphan drug designation (ODD) for the treatment of malignant mesothelioma by the European...